Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 6:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 148 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Transdermal nicotine Clear all
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia

NCT03838484
View directory record Official record
Conditions
Schizophrenia, Impulsive Behavior
Interventions
Nicotine Patch, 7 Mg/24 Hr, Placebo patch
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 5, 2026, 6:01 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Comparing Smoking Treatment Programs for Lighter Smokers - 1

NCT00086411
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
nicotine transdermal system, bupropion, Medication Management, Mayo Counseling, placebo patch, placebo bupropion
Drug · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Sep 5, 2026, 6:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)

NCT05136690
View directory record Official record
Conditions
Cognitive Impairment Associated With Schizophrenia
Interventions
Nicotine patch, MK-4334, Placebo patch, Placebo capsule
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Long Beach, California • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Sep 5, 2026, 6:01 AM EDT
Completed Not applicable Interventional Results available

Patch Study - Intervention for HIV Positive Smokers

NCT02982772
View directory record Official record
Conditions
Smoking Cessation, HIV
Interventions
Combination Therapy, Standard Care Intervention
Other
Lead sponsor
dr. maria miguez
Other
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Sep 5, 2026, 6:01 AM EDT
Completed Not applicable Interventional

Contingency Management for Smoking Cessation in the Homeless

NCT01736982
View directory record Official record
Conditions
Cigarette Smoking
Interventions
Contingency Management, Standard of Care
Behavioral · Other
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New Britain, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 15, 2018 · Synced Sep 5, 2026, 6:01 AM EDT
Terminated Phase 2 Interventional Results available

Study of Nicotine for Pain Associated With Chemotherapy-Induced Peripheral Neuropathy

NCT04468230
View directory record Official record
Conditions
Neuropathy, Peripheral Neuropathy, Neuropathic Pain, Chemotherapy-induced Peripheral Neuropathy
Interventions
Nicotine Transdermal Patch
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Sep 5, 2026, 6:01 AM EDT
Completed Phase 3 Interventional

An Open Label Study That Compares Varenicline to Transdermal Nicotine Patch for Smoking Cessation

NCT00143325
View directory record Official record
Conditions
Smoking Cessation
Interventions
varenicline (CP-526,555)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
6
States / cities
Palo Alto, California • Santa Ana, California • Farmington, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2007 · Synced Sep 5, 2026, 6:01 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Behavioral Intervention for Low Income Depressed Smokers in Drug Treatment

NCT01372254
View directory record Official record
Conditions
Cigarette Smoking, Drug Use
Interventions
Standard Treatment, BAD-AS, Transdermal Nicotine Patch
Behavioral · Drug
Lead sponsor
University of Maryland, College Park
Other
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Sep 5, 2026, 6:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nicotine Patch, Blood Flow and Oxidative Stress Study

NCT00954096
View directory record Official record
Conditions
Healthy
Interventions
transdermal nicotine patch (7mg)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 26, 2009 · Synced Sep 5, 2026, 6:01 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Behavioral Activation Therapy and Nicotine Replacement Therapy in Increasing Smoking Cessation

NCT02697227
View directory record Official record
Conditions
Cigarette Smoker, Tobacco Use Disorder
Interventions
Behavioral Intervention, Laboratory Biomarker Analysis, Nicotine Patch, Questionnaire Administration, Smoking Cessation Intervention
Behavioral · Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 5, 2026, 6:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Bioequivalence Study of 21 Milligram (mg) Nicotine Transdermal Patches (NicoDerm CQ, GlaxoSmithKline [GSK] Dungarvan) Compared to the Current Marketed 21 mg Nicotine Transdermal Patches (NicoDerm CQ, Alza) in Healthy Adult Smokers

NCT05024747
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
NicoDerm CQ patch (GSK Dungarvan), NicoDerm CQ (Alza)
Drug
Lead sponsor
HALEON
Industry
Eligibility
21 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Sep 5, 2026, 6:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Attention Deficit Hyperactivity Disorder (ADHD) Smoking Cessation Study

NCT00736255
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Nicotine Dependence
Interventions
Transdermal Nicotine Patch, Lis-dexamphetamine (Vyvanse), Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Sep 5, 2026, 6:01 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Comparing Two Treatments That Both Target Smoking Cessation and Weight Loss at the Same Time.

NCT04130698
View directory record Official record
Conditions
Smoking Cessation, Weight Loss
Interventions
Distress Tolerance, transdermal nicotine patch, Active Health Control
Behavioral · Drug
Lead sponsor
Rhode Island College
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Sep 5, 2026, 6:01 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Remote vs. In-Person Study Evaluation (RISE) Trials: RISE Above Smoking (Trial 1)

NCT06822049
View directory record Official record
Conditions
Remote vs. In-Person, Remote Visits, In-person Visits
Interventions
Combination Nicotine Replacement Therapy (patch and lozenge)
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Buffalo, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 5, 2026, 6:01 AM EDT
Active, not recruiting Not applicable Interventional

Smoking Cessation Intervention for Cancer Patients

NCT00575718
View directory record Official record
Conditions
Newly Diagnosed Cancer Patients
Interventions
Hospital Counseling + Nicotine Replacement Therapy. questionaires, Hospital Counseling + Nicotine Replacement + Presurgical Scheduled Reduced Smoking, questionaires
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Sep 5, 2026, 6:01 AM EDT
Terminated Not applicable Interventional

Project QUIT+: Adapting and Testing a Smoking Cessation Intervention for Transgender and Gender Expansive Individuals

NCT06654414
View directory record Official record
Conditions
Smoking Cessation, Depression, Anxiety, Nicotine Dependence, Gender Minority Stress
Interventions
PRIDE QUIT, Enhanced Treatment As Usual (ETAU)
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Sep 5, 2026, 6:01 AM EDT
Not listed Phase 1 Interventional

Nicotine Treatment of Mild Cognitive Impairment (MCI)

NCT00091468
View directory record Official record
Conditions
Age-Related Memory Disorders
Interventions
Transdermal nicotine patch, Placebo transdermal patch
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
55 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Durham, North Carolina • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Sep 5, 2026, 6:01 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia

NCT00218218
View directory record Official record
Conditions
Schizophrenia and Disorders With Psychotic Features, Tobacco Use Disorder, Schizophrenia
Interventions
Transdermal Nicotine Patch, 21 mg transdermal nicotine, placebo patch
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 5, 2026, 6:01 AM EDT
Terminated Phase 2 Interventional Results available

Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer

NCT00751101
View directory record Official record
Conditions
Breast Cancer, Chemotherapeutic Agent Toxicity, Palmar-plantar Erythrodysesthesia
Interventions
Nicotine patch
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Sep 5, 2026, 6:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation

NCT02859142
View directory record Official record
Conditions
Smoking Cessation, Alcohol Drinking
Interventions
Chantix, Behavioral Counseling Sessions, NicodermCQ, Placebo
Drug · Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 85 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 26, 2021 · Synced Sep 5, 2026, 6:01 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Nicotine Treatment of Cognitive Decline in Down Syndrome

NCT01778946
View directory record Official record
Conditions
Down Syndrome, Mild Cognitive Impairment
Interventions
Low Dose Nicotine (7mg), Moderate Dose Nicotine (14mg)
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
25 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Sep 5, 2026, 6:01 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Tailored Tobacco Quitline for Rural Veterans

NCT01592695
View directory record Official record
Conditions
Cigarette Smoking
Interventions
Nicotine replacement therapy - transdermal nicotine patch, Tailored behavioral intervention, Tobacco quit line referral, Nicotine replacement therapy - nicotine gum, Nicotine replacement therapy - nicotine lozenge, Bupropion Sustained Release, Varenicline, Combination pharmacotherapy - transdermal nicotine patch + nicotine gum, Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge, Combination pharmacotherapy - transdermal nicotine patch + bupropion, Alcohol use risk reduction, Behavioral activation for the treatment of depression, Behavioral management of post-cessation weight gain
Drug · Behavioral
Lead sponsor
Iowa City Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 99 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Sep 5, 2026, 6:01 AM EDT
Completed Phase 4 Interventional Results available

Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking

NCT00365508
View directory record Official record
Conditions
Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions
nicotine lozenge, nicotine patch
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
642 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
10
States / cities
Washington D.C., District of Columbia • Miami Beach, Florida • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Sep 5, 2026, 6:01 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

PET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine.

NCT07095205
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Nicotine transdermal patch, PET Scan with [18F] VAT
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Sep 5, 2026, 6:01 AM EDT